Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice

被引：0
|
作者：
Jadvar, Hossein [1 ,2 ]
Iravani, Amir [3 ]
Bodei, Lisa [4 ]
Calais, Jeremie [5 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Div Nucl Med, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Mol Imaging Ctr, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA
[3] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[5] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 12期
关键词：
RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; PSMA PET/CT; 177LU-PSMA-617; MULTICENTER; SAFETY;
D O I：
10.2967/jnumed.124.268023
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1851 / 1854
页数：4
相关论文
共 50 条
  • [41] First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
    Nulent, Thomas J. W. Klein
    van Es, Robert J. J.
    Willems, Stefan M.
    Braat, Arthur J. A. T.
    Devriese, Lot A.
    de Bree, Remco
    de Keizer, Bart
    EJNMMI RESEARCH, 2021, 11 (01)
  • [42] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [43] Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Lee, Vivian
    O'Brien, Sophia
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (04) : 301 - 304
  • [44] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [45] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [46] Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
    Ahmadzadehfar, Hojjat
    Essler, Markus
    Schaefers, Michael
    Rahbar, Kambiz
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 835
  • [47] Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
    Wang, Jingnan
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Li, Fang
    Lin, Yansong
    Huo, Li
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 431 - 438
  • [48] Correlation of PSMA PET and Post-therapy SPECT Imaging Metrics with Absorbed Doses for 177Lu-PSMA-617 Therapy
    Meyer, Catherine
    Yilmaz, Burcak
    Winters, Celeste
    Mench, Anna
    Mallak, Nadine
    Mittra, Erik
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [49] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
    Mateo, Joaquin
    Zurita, Amado J.
    LANCET, 2024, 404 (10459): : 1174 - 1176
  • [50] Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient
    Usmani, Sharjeel
    Al Kandari, Fareeda
    Alrekhais, Ibrahim
    N. Khalaf, Shatha
    Ahmed, Najeeb
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (02) : E213 - E214
12345